Analysis by GlobalData characterises an uncertain pharma landscape, though big pharma CEOs allay investor concern.

Sandoz will acquire Just – Evotec Biologics’ biosimilar development and manufacturing plant in Toulouse for $300m.

Regeneron has received an US Food and Drug Administration (FDA) rejection for a new blood cancer therapy and expects separate regulatory delays for blockbuster ophthalmology drug Eylea HD due to ...

Atombeat and BioDuro have announced a strategic partnership to launch an AI-powered platform aimed at accelerating peptide drug discovery.

Arrowhead's subsidiary Visirna has entered an agreement with Sanofi for plozasiran, a potential treatment for hypertriglyceridemia.

Europe’s cannabis pharmaceutical sector is shifting as scientific rigour, regulatory clarity and cautious capital define its next chapter.

Despite being significantly lower than the 200% rate threatened by Trump, the deal is set to ramp up drug costs by billions.

Major pharma manufacturers have a 29 September deadline to adjust their drug prices relative to other developed countries.

Biotechs investigate mitochondria-targeting drugs to claim a share in the weight loss drug market dominated by GLP-1RAs.

Just one day after CEO Stéphane Bancel’s sudden announcement of a 10% workforce reduction, Moderna has released Q2 2025 that that fell short of analyst expectations.

MetrioPharm’s lead compound, MP1032, has received ODD from the European Medicines Agency (EMA) for treating DMD in children.

Tidmarsh will temporarily guide CBER’s regulatory activities while the FDA searches for a permanent department lead.